0.245
-0.015
(-5.77%)
Jun 18 - Close
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.24 - 0.26 |
| 52 week | 0.14 - 0.37 |
| Open | 0.26 |
| Vol / Avg. | 49,651.00/65,277.00 |
| Mkt cap | 27.90M |
| P/E | - |
| Div/yield | - |
| EPS | -0.07 |
| Shares | 113.88M |
| Beta | 0.71 |
| Inst. own | - |
Events
Aug 12, 2013
Q2 2013 Spectral Diagnostics Inc Earnings Release
May 23, 2013
Spectral Diagnostics Inc Annual Shareholder Meeting
May 15, 2013
Q1 2013 Spectral Diagnostics Inc Earnings Release (Tentative)
|
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -311.39% | -276.26% |
| Operating margin | -314.09% | -278.93% |
| EBITD margin | - | -265.84% |
| Return on average assets | -54.55% | -35.38% |
| Return on average equity | -61.09% | -38.57% |
| Employees | 16 | - |
| Carbon Disclosure Rating | - | - |
Address
135-2 The West Mall
TORONTO, ON M9C 1C2
Canada
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)
TORONTO, ON M9C 1C2
Canada
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Spectral Diagnostics Inc. (Spectral) focuses on the development and commercialization, in North America, treatment for severe sepsis and septic shock. The Company also manufactures and sells certain reagents. Its products include Rapid Diagnostics for Sepsis, Endotoxin Activity Assay (EAA) and Toraymyxin. As of December 31, 2011, Spectral�s EAA endotoxin measurement was the only the United Sates Food and Drug Administration (FDA) cleared diagnostic on the market. Spectral Diagnostics (US) Inc. and Spectral Diagnostics (New Brunswick) Inc. are its subsidiaries.
Officers and directors
| Anthony P. Bihl III | Chairman of the Board | |
| Paul M. Walker M.D., Ph.D | President, Chief Executive Officer, Director | |
| Anthony Businskas | Chief Financial Officer, Executive Vice President, Corporate Secretary | |
| Guadagni Guadagni | Vice President - Sales and Marketing | |
| Debra M Foster RN | Vice President - Clinical Development | |
| Robert A. Verhagen | Vice President - Business Development | |
| R. Ian Lennox | Lead Independent Director | |
| Guillermo A. Herrera | Independent Director | |
| Edward E. McCormack | Independent Director | |
| Laine M. Woollard Q.C. | Independent Director |